|
1
|
Yang JD, Hainaut P, Gores GJ, Amadou A,
Plymoth A and Roberts LR: A global view of hepatocellular
carcinoma: Trends, risk, prevention and management. Nat Rev
Gastroenterol Hepatol. 16:589–604. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Llovet JM, Zucman-Rossi J, Pikarsky E,
Sangro B, Schwartz M, Sherman M and Gores G: Hepatocellular
carcinoma. Nat Rev Dis Primers. 2:160182016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Roayaie S, Jibara G, Tabrizian P, Park JW,
Yang J, Yan L, Schwartz M, Han G, Izzo F, Chen M, et al: The role
of hepatic resection in the treatment of hepatocellular cancer.
Hepatology. 62:440–451. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kulik L and El-Serag HB: Epidemiology and
management of hepatocellular carcinoma. Gastroenterology.
156:477–491.e1. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Galle PR, Forner A, Llovet JM, Mazzaferro
V, Piscaglia F, Raoul JL, Schirmacher P and Vilgrain V; European
Association for the Study of the Liver. Electronic address, :
easloffice@easloffice.eu; European Association for the Study of the
Liver: EASL Clinical Practice Guidelines: Management of
hepatocellular carcinoma. J Hepatol. 69:182–236. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhu AX, Kudo M, Assenat E, Cattan S, Kang
YK, Lim HY, Poon RT, Blanc JF, Vogel A, Chen CL, et al: Effect of
everolimus on survival in advanced hepatocellular carcinoma after
failure of sorafenib: The EVOLVE-1 randomized clinical trial. JAMA.
312:57–67. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lopez PM, Villanueva A and Llovet JM:
Systematic review: Evidence-based management of hepatocellular
carcinoma - an updated analysis of randomized controlled trials.
Aliment Pharmacol Ther. 23:1535–1547. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Patop IL, Wüst S and Kadener S: Past,
present, and future of circRNAs. EMBO J. 38:e1008362019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jeck WR, Sorrentino JA, Wang K, Slevin MK,
Burd CE, Liu J, Marzluff WF and Sharpless NE: Circular RNAs are
abundant, conserved, and associated with ALU repeats. RNA.
19:141–157. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Han TS, Hur K, Cho HS and Ban HS:
Epigenetic associations between lncRNA/circRNA and miRNA in
hepatocellular carcinoma. Cancers (Basel). 12:26222020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cui W and Xue J: Circular RNA DOCK1
downregulates microRNA-124 to induce the growth of human thyroid
cancer cell lines. Biofactors. 46:591–599. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu P, Li X, Guo X, Chen J, Li C, Chen M,
Liu L, Zhang X and Zu X: Circular RNA DOCK1 promotes bladder
carcinoma progression via modulating circDOCK1/hsa-miR-132-3p/Sox5
signalling pathway. Cell Prolif. 52:e126142019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang L, Wei Y, Yan Y, Wang H, Yang J,
Zheng Z, Zha J, Bo P, Tang Y, Guo X, et al: CircDOCK1 suppresses
cell apoptosis via inhibition of miR 196a 5p by targeting BIRC3 in
OSCC. Oncol Rep. 39:951–966. 2018.PubMed/NCBI
|
|
14
|
Kong R: Circular RNA hsa_circ_0085131 is
involved in cisplati-resistance of non-small-cell lung cancer cells
by regulating autophagy. Cell Biol Int. 44:1945–1956. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Huang F, Wu X, Wei M, Guo H, Li H, Shao Z,
Wu Y and Pu J: miR-654-5p Targets HAX-1 to regulate the nalignancy
behaviors of colorectal cancer cells. BioMed Res Int.
2020:49147072020.PubMed/NCBI
|
|
16
|
Majem B, Parrilla A, Jiménez C,
Suárez-Cabrera L, Barber M, Marín A, Castellví J, Tamayo G,
Moreno-Bueno G, Ponce J, et al: MicroRNA-654-5p suppresses ovarian
cancer development impacting on MYC, WNT and AKT pathways.
Oncogene. 38:6035–6050. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang JX, He WL, Feng ZH, Chen DL, Gao Y,
He Y, Qin K, Zheng ZS, Chen C, Weng HW, et al: A positive feedback
loop consisting of C12orf59/NF-κB/CDH11 promotes gastric cancer
invasion and metastasis. J Exp Clin Cancer Res. 38:1642019.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zheng S, Jia Q, Shen H, Xu X, Ling J, Jing
C and Zhang B: Treatment with the herbal formula Songyou Yin
inhibits epithelial-mesenchymal transition in hepatocellular
carcinoma through downregulation of TGF-β1 expression and
inhibition of the SMAD2/3 signaling pathway. Oncol Lett.
13:2309–2315. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zheng X, Gai X, Han S, Moser CD, Hu C,
Shire AM, Floyd RA and Roberts LR: The human sulfatase 2 inhibitor
2,4-disulfonylphenyl-tert-butylnitrone (OKN-007) has an antitumor
effect in hepatocellular carcinoma mediated via suppression of
TGFB1/SMAD2 and Hedgehog/GLI1 signaling. Genes Chromosomes Cancer.
52:225–236. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang J, Liu G, Li Q, Wang F, Xie F, Zhai
R, Guo Y, Chen T, Zhang N, Ni W, et al: Mucin1 promotes the
migration and invasion of hepatocellular carcinoma cells via
JNK-mediated phosphorylation of Smad2 at the C-terminal and linker
regions. Oncotarget. 6:19264–19278. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Forner A, Reig M and Bruix J:
Hepatocellular carcinoma. Lancet. 391:1301–1314. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Qin M, Liu G, Huo X, Tao X, Sun X, Ge Z,
Yang J, Fan J, Liu L and Qin W: Hsa_circ_0001649: A circular RNA
and potential novel biomarker for hepatocellular carcinoma. Cancer
Biomark. 16:161–169. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fu L, Wu S, Yao T, Chen Q, Xie Y, Ying S,
Chen Z, Xiao B and Hu Y: Decreased expression of hsa_circ_0003570
in hepatocellular carcinoma and its clinical significance. J Clin
Lab Anal. 32:e222392018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fu L, Chen Q, Yao T, Li T, Ying S, Hu Y
and Guo J: Hsa_circ_0005986 inhibits carcinogenesis by acting as a
miR-129-5p sponge and is used as a novel biomarker for
hepatocellular carcinoma. Oncotarget. 8:43878–43888. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liang WC, Wong CW, Liang PP, Shi M, Cao Y,
Rao ST, Tsui SK, Waye MM, Zhang Q, Fu WM, et al: Translation of the
circular RNA circβ-catenin promotes liver cancer cell growth
through activation of the Wnt pathway. Genome Biol. 20:842019.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xu XZ, Song H, Zhao Y and Zhang L:
MiR-654-5p regulated cell progression and tumor growth through
targeting SIRT6 in osteosarcoma. Eur Rev Med Pharmacol Sci.
24:3517–3525. 2020.PubMed/NCBI
|
|
28
|
Tan YY, Xu XY, Wang JF, Zhang CW and Zhang
SC: MiR-654-5p attenuates breast cancer progression by targeting
EPSTI1. Am J Cancer Res. 6:522–532. 2016.PubMed/NCBI
|
|
29
|
Li ZY, Wang XL, Dang Y, Zhu XZ, Zhang YH,
Cai BX and Zheng L: Long non-coding RNA UCA1 promotes the
progression of paclitaxel resistance in ovarian cancer by
regulating the miR-654-5p/SIK2 axis. Eur Rev Med Pharmacol Sci.
24:591–603. 2020.PubMed/NCBI
|
